Oncobiologics (OTLK)
(Real Time Quote from BATS)
$10.87 USD
+1.50 (16.01%)
Updated Mar 28, 2024 11:22 AM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Oncobiologics, Inc falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 23 | 17 | 14 | 13 | 8 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 10 | 7 | 5 | 5 |
Total Current Assets | 31 | 28 | 22 | 18 | 14 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 3 |
Investments & Advances | 1 | 1 | 1 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 1 | 0 |
Total Assets | 32 | 29 | 23 | 20 | 17 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 4 | 4 |
Accounts Payable | 7 | 3 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 36 | 11 | 1 | 0 | 8 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 2 | 8 | 5 |
Income Taxes Payable | 2 | 2 | 2 | 2 | 2 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 47 | 20 | 7 | 16 | 20 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 11 | 1 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 3 |
Other Non-Current Liabilities | 0 | 0 | 1 | 0 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 47 | 20 | 18 | 17 | 28 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 5 |
Common Stock (Par) | 3 | 2 | 2 | 1 | 0 |
Capital Surplus | 451 | 415 | 346 | 291 | 238 |
Retained Earnings | -468 | -409 | -343 | -290 | -254 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -14 | 9 | 5 | 3 | -11 |
Total Liabilities & Shareholder's Equity | 32 | 29 | 23 | 20 | 17 |
Total Common Equity | -14 | 9 | 5 | 3 | -16 |
Shares Outstanding | 13.00 | 11.30 | 8.80 | 6.30 | 1.40 |
Book Value Per Share | -1.11 | 0.77 | 0.52 | 0.45 | -11.52 |
Fiscal Year End for Oncobiologics, Inc falls in the month of September.
All items in Millions except Per Share data.
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10 | 23 | 34 | 44 | 52 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 10 | 8 | 9 | 9 | 9 |
Total Current Assets | 20 | 31 | 43 | 53 | 62 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 1 | 1 | 1 | 1 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 1 | 0 | 0 |
Total Assets | 22 | 32 | 44 | 54 | 63 |
Liabilities & Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 7 | 5 | 4 | 4 |
Current Portion Long-Term Debt | 37 | 36 | 35 | 32 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 3 | 8 | 6 | 9 |
Income Taxes Payable | 2 | 2 | 2 | 2 | 2 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 46 | 47 | 50 | 44 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 32 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 46 | 47 | 50 | 44 | 47 |
Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 3 |
Capital Surplus | 452 | 451 | 447 | 442 | 441 |
Retained Earnings | -479 | -468 | -455 | -434 | -428 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -24 | -14 | -6 | 10 | 16 |
Total Liabilities & Shareholder's Equity | 22 | 32 | 44 | 54 | 63 |
Total Common Equity | -24 | -14 | -6 | 10 | 16 |
Shares Outstanding | 13.00 | 13.00 | 12.80 | 12.80 | 12.80 |
Book Value Per Share | -1.87 | -1.11 | -0.43 | 0.82 | 1.23 |